<DOC>
	<DOCNO>NCT02823951</DOCNO>
	<brief_summary>The purpose study evaluate proportion patient demonstrate medical need discontinue therapy among DMT-naïve patient relapse form multiple sclerosis 1 year treatment Rebif 44 mcg tiw Tecfidera 240 mg bid base real-world data .</brief_summary>
	<brief_title>Patient Real-world Clinical , Neurological , Tolerability , Safety Outcomes Tecfidera® Rebif® : A Retrospective Study</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>1 . Diagnosis Clinically Isolated Syndrome ( CIS ) relapse remit multiple sclerosis ( RRMS ) . 2 . Age 18 55 year time index . 3 . No evidence prior disease modify therapy MS. 4 . Initiated treatment either Rebif Tecfidera time index . Patient consider initiated treatment take least one dose . Treatment must initiate product approved FDA . 5 . Availability high quality baseline MRI brain scan , must occur 6 month prior index date 2 week index date . 6 . Availability clinical data patient 's record full study observation period , define primary objective . 1 . Pregnant time study observation period . 2 . Presence preexist medical condition know associated brain pathology ( cerebrovascular neurodegenerative disease , presence active alcohol substance abuse ) . 3 . Patient discontinue initial therapy prior complete 1 year treatment due reason disease activity , tolerability , safety ( e.g . financial , convenience , preference , etc. ) . 4 . Phase III registrational trial patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>